peptide garden
Menu
Peptide Profile

Retatrutide

Retatrutide (LY3437943)

An investigational triple GIP/GLP-1/glucagon receptor agonist from Eli Lilly. Pivotal Phase 3 data: up to 28.3% weight loss (TRIUMPH-1, n=2,339), with TRANSCEND-T2D-1 now peer-reviewed in The Lancet. Not yet FDA-approved.

Reviewed June 27, 2026·20 min read·12 citations·Not approvedPhase 3 trials
On this page

At a glance

Retatrutide is the first triple receptor agonist -- a single peptide that activates GIP, GLP-1, and glucagon receptors simultaneously. It is not FDA-approved and is currently in Phase 3 clinical trials (the TRIUMPH and TRANSCEND programs) conducted by Eli Lilly. Three Phase 3 readouts are now available, including the pivotal obesity trial: TRIUMPH-1 (n=2,339) showed up to 28.3% weight loss at 80 weeks, TRIUMPH-4 showed up to 28.7% at 68 weeks, and TRANSCEND-T2D-1 — the first peer-reviewed Phase 3 RCT, published in The Lancet — showed A1C reductions up to 1.94% and 15.3% weight loss in type 2 diabetes at 40 weeks.

Animal studiesStrongExtensive preclinical

Comprehensive preclinical pharmacology published in Cell Metabolism (Coskun 2022). Triple agonist synergy demonstrated across multiple animal models showing enhanced weight loss, glycemic control, and hepatic fat reduction beyond dual agonists.

Human evidenceModerate~4,100 participants

Three Phase 2 RCTs (n=878) published in NEJM, Lancet, and Nature Medicine. Three Phase 3 topline readouts now reported, including the pivotal obesity trial: TRIUMPH-1 (n=2,339, general obesity), TRIUMPH-4 (n=445, obesity/knee OA), and TRANSCEND-T2D-1 (n=537, T2D monotherapy). The first peer-reviewed Phase 3 RCT — TRANSCEND-T2D-1 — was published in The Lancet (June 2026). Up to 28.3% weight loss (TRIUMPH-1) and A1C reductions up to 1.94%. Remaining Phase 3 publications still pending. Not yet FDA-approved.

Safety dataModerate~4,100 participants

Safety data from ~4,100 participants across Phase 2 and Phase 3 trials. GI side-effect profile consistent with GLP-1 class. Dysesthesia signal dose-dependent but variable: 20.9% at 12 mg in TRIUMPH-4, 12.5% in the larger TRIUMPH-1, and 2.3-4.5% in TRANSCEND-T2D-1. ADA 2026 also flagged a new urinary tract infection signal in TRIUMPH-1 (7.5-8.8% of treated participants vs. 5.3% placebo, predominantly in women, generally mild-to-moderate and mostly self-resolving). AE discontinuations 11.3% at 12 mg vs. 4.9% placebo in TRIUMPH-1. No post-marketing surveillance data. Long-term safety unknown.

How are these scores calculated?

Retatrutide is an investigational drug -- it has not been approved by the FDA or any regulatory agency. The evidence is promising and now includes three Phase 3 topline readouts — including the pivotal obesity trial TRIUMPH-1 — and the first peer-reviewed Phase 3 RCT (TRANSCEND-T2D-1, published in The Lancet). What that means: the data is striking across weight loss, diabetes, sleep apnea, and joint pain, but we are still waiting for the remaining peer-reviewed publications, long-term safety data, and regulatory review. It is not available by prescription or at pharmacies.

New research, delivered clearly

When new studies publish or clinical trials report results, we'll break them down in plain language.

Quick facts

Molecular weight
4,731.33 Da
Amino acids
39 (with Aib and αMeL modifications)
Half-life
~6 days (once-weekly dosing)
Developer
Eli Lilly and Company
FDA status
Not approved (Phase 3)
WADA status
Monitoring Program (not prohibited)

Amino acid sequence

YA\u0302QGTFTSDYSIL*LDKK\u2020AQA\u0302AFIEYLLEGGPSSGAPPPS-NH\u2082

What is retatrutide?

Retatrutide is a synthetic peptide -- a 39-amino-acid chain -- that simultaneously activates three receptors for metabolic hormones: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon.[5] This triple-receptor approach makes it a "triagonist" and distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GIP + GLP-1).

The compound is being developed by Eli Lilly and Company under the research code LY3437943. Preclinical and Phase 1 data were published in 2022, followed by two landmark Phase 2 trials in 2023 that generated significant attention: one showed up to 24.2% body weight loss in people with obesity, and another showed HbA1c below 6.5% in up to 82% of people with type 2 diabetes.[1][2]

Retatrutide is structurally similar to tirzepatide -- both are built on a GIP backbone, both use Aib residues for DPP-4 resistance, and both use a fatty acid moiety for albumin binding. The critical difference is the addition of glucagon receptor agonism, which is believed to drive increased energy expenditure and liver fat reduction -- effects not seen with GLP-1 or GIP agonism alone.

Important: Retatrutide is not FDA-approved and is not available by prescription, at pharmacies, or through compounding. It is only available through enrollment in clinical trials. Any commercial sale of retatrutide is unauthorized.

How it works

In plain terms, retatrutide mimics three gut and metabolic hormones that your body naturally uses to regulate blood sugar, appetite, and energy balance. By activating all three pathways at once, it produces stronger effects on weight and metabolism than drugs that target only one or two.[5]

Think of it as working on three channels simultaneously: one primarily affecting insulin response and fat metabolism (GIP), another primarily affecting appetite and glucose regulation (GLP-1), and a third promoting energy expenditure and liver fat breakdown (glucagon). The combination appears to produce more than the sum of its parts.

Detailed mechanism (for advanced readers)

Retatrutide is a triple receptor agonist targeting GIP, GLP-1, and glucagon receptors:[5]

GIP receptor agonism (highest potency):

  • Full agonist at the GIP receptor -- this is the dominant receptor interaction (similar to tirzepatide)
  • GIP signaling in adipose tissue promotes lipid storage regulation and improves insulin sensitivity
  • GIP receptor activation in the brain may contribute to appetite suppression
  • Retatrutide is more potent at the GIP receptor than at native GIP

GLP-1 receptor agonism:

  • Glucose-dependent insulin secretion from pancreatic beta cells
  • Glucagon suppression from alpha cells
  • Delayed gastric emptying (contributes to satiety and GI side effects)
  • Central appetite regulation via hypothalamic and brainstem GLP-1 receptors
  • Lower potency at GLP-1R compared to native GLP-1

Glucagon receptor agonism (the key differentiator):

  • Promotes hepatic lipid oxidation and reduces liver fat -- explains the dramatic MASLD results
  • Increases energy expenditure through thermogenesis
  • Mobilizes hepatic glycogen and fatty acids
  • May contribute to greater overall weight loss beyond GIP/GLP-1 effects
  • This is what distinguishes retatrutide from both semaglutide and tirzepatide

Structural modifications:

  • Two Aib (alpha-aminoisobutyric acid) residues at positions 2 and 20 for DPP-4 resistance
  • Alpha-methyl-L-leucine at position 13 for additional stability
  • C20 fatty diacid moiety attached via Lys17 enables albumin binding
  • Half-life of approximately 6 days enables once-weekly dosing

How it differs from tirzepatide: Tirzepatide activates GIP and GLP-1 receptors but has no glucagon receptor activity. Retatrutide adds glucagon receptor agonism, which drives increased energy expenditure and hepatic fat reduction. This may explain the ~5-8 percentage points of additional weight loss seen in cross-trial comparisons.[7]

What the research says

Retatrutide has produced the highest weight loss numbers ever reported for a pharmaceutical agent -- up to 24.2% in Phase 2 and 28.3% at 12 mg in the pivotal Phase 3 TRIUMPH-1 trial (n=2,339), with nearly half of that group losing 30%-plus — comparable to bariatric surgery. The data is striking, and the first peer-reviewed Phase 3 RCT is now published in The Lancet, but the evidence base is still maturing: most Phase 3 publications are still pending and FDA review has not begun.

Peptide Garden evidence assessment, June 2026

Research timeline

Retatrutide's development has moved rapidly from preclinical work to Phase 3 trials:

  1. 2020Preclinical

    Discovery and early development

    Eli Lilly develops LY3437943 as a novel triple GIP/GLP-1/glucagon receptor agonist. First-in-human Phase 1 study begins.

  2. 2022Preclinical

    Preclinical and Phase 1 data published

    Coskun et al. publish the foundational paper in Cell Metabolism, establishing triple agonist pharmacology and reporting Phase 1 proof-of-concept results in healthy volunteers and people with T2D.

  3. 2023Human study

    Phase 2 results generate major attention

    Two landmark Phase 2 trials published: Jastreboff et al. (NEJM) report 24.2% weight loss in obesity; Rosenstock et al. (Lancet) report HbA1c <6.5% in 82% of T2D participants. Phase 3 TRIUMPH program begins enrollment.

  4. 2024Human study

    MASLD data published; Phase 3 enrollment continues

    Sanyal et al. (Nature Medicine) report 82% liver fat reduction in MASLD. TRIUMPH Phase 3 program enrolls 5,800+ participants across four registrational trials.

  5. 2025Human study

    First Phase 3 results (TRIUMPH-4)

    Eli Lilly announces topline results: 28.7% weight loss at 12 mg and substantial knee OA pain relief in TRIUMPH-4 (n=445). Dysesthesia safety signal emerges at 20.9% (12 mg).

  6. 2026Human study

    Pivotal Phase 3 obesity data (TRIUMPH-1) and first peer-reviewed Phase 3 RCT

    March 2026: TRANSCEND-T2D-1 topline results in T2D monotherapy (n=537), with dysesthesia rates of 2.3-4.5%. May 21, 2026: the pivotal TRIUMPH-1 obesity trial (n=2,339, without diabetes) reports 28.3% weight loss at 12 mg over 80 weeks, with 45.3% losing ≥30% and a 104-week extension up to 30.3%. June 6, 2026: TRANSCEND-T2D-1 is published in The Lancet (Bajaj et al., 15.3% weight loss, A1C reductions up to 1.94%, 82-89% reaching A1C <7.0%); ADA 2026 also reports TRIUMPH-1 nested sleep apnea (AHI −36.1 events/hr) and knee-OA (WOMAC pain −73.1%) data. TRIUMPH-2 (T2D + obesity) and TRIUMPH-3 (OSA) results still anticipated.

Human clinical trials

Retatrutide has been studied in Phase 2 trials with a combined enrollment of approximately 878 participants, plus three reported Phase 3 trials: TRIUMPH-1 (2,339 participants), TRIUMPH-4 (445 participants), and TRANSCEND-T2D-1 (537 participants):

Phase 2 program: Three trials -- obesity without T2D (NEJM), type 2 diabetes (Lancet), and MASLD/fatty liver disease (Nature Medicine) -- established dose-response relationships and a safety profile.[1][2][3]

Phase 3 TRIUMPH program: Four registrational trials enrolling over 5,800 participants, evaluating obesity, T2D with obesity, obstructive sleep apnea, and knee osteoarthritis. TRIUMPH-4 (knee OA) reported in December 2025; the pivotal TRIUMPH-1 (general obesity, n=2,339) reported topline results on May 21, 2026, with nested sleep-apnea and knee-OA basket data presented at ADA 2026.[6][4][10]

Phase 3 TRANSCEND program: Evaluates retatrutide specifically for type 2 diabetes. TRANSCEND-T2D-1 (n=537) reported topline in March 2026 and was published in The Lancet on June 6, 2026 — the first peer-reviewed Phase 3 RCT for retatrutide — showing A1C reductions up to 1.94% and 15.3% weight loss as monotherapy.[9]

2023·Phase 2, double-blind, randomized, placebo-controlled·n=338High quality

Phase 2: Retatrutide for obesity (Jastreboff 2023)

Obesity or overweight (BMI 30+ or 27+ with comorbidity)

Weight loss of 8.7% (1 mg), 17.1% (4 mg), 22.8% (8 mg), and 24.2% (12 mg) vs. 2.1% placebo at 48 weeks. At 12 mg, 100% of participants lost 5%+ and 83% lost 15%+ of body weight. Weight loss curves had not plateaued at 48 weeks.

2023·Phase 2, double-blind, randomized, placebo and active-controlled·n=281High quality

Phase 2: Retatrutide in type 2 diabetes (Rosenstock 2023)

Type 2 diabetes mellitus

HbA1c <6.5% achieved in up to 82%. Weight loss up to 16.94% (12 mg) at 36 weeks vs. 3.0% placebo and 2.0% dulaglutide 1.5 mg. Dose-dependent improvements in glycemic control and body weight.

2024·Phase 2a, double-blind, randomized, placebo-controlled·n=98Moderate quality

Phase 2a: Retatrutide for MASLD/fatty liver (Sanyal 2024)

Metabolic dysfunction-associated steatotic liver disease (MASLD)

Liver fat reduced by up to 82.4% (12 mg) vs. +0.3% placebo at 24 weeks. Normal liver fat (<5%) achieved by 86% of the 12 mg group vs. 0% of the placebo group. Dramatic reductions attributed to glucagon receptor-mediated hepatic lipid oxidation.

2025·Phase 3, double-blind, randomized, placebo-controlled·n=445High quality

TRIUMPH-4: Obesity with knee osteoarthritis (Phase 3)

Obesity or overweight with knee osteoarthritis

Weight loss of 26.4% (9 mg) and 28.7% (12 mg) vs. placebo at 68 weeks. WOMAC knee pain scores reduced by up to 75.8%. Over 1 in 8 patients became completely pain-free. First Phase 3 data. Dysesthesia signal at 20.9% (12 mg).

2026·Phase 3, double-blind, randomized, placebo-controlled·n=537High quality

TRANSCEND-T2D-1: Retatrutide monotherapy for type 2 diabetes (Phase 3, Lancet 2026)

Type 2 diabetes mellitus (monotherapy)

Peer-reviewed in The Lancet (Bajaj 2026). A1C reductions of 1.69% (4 mg), 1.86% (9 mg), 1.94% (12 mg) vs. 0.81% placebo at 40 weeks (baseline 7.9%); 82-89% reached A1C <7.0%. Weight loss 15.3% (12 mg) in the Lancet analysis — the topline press release reported 16.8% (36.6 lb). Dysesthesia 2.3-4.5%, much lower than TRIUMPH-4's 20.9%.

2026·Phase 3, double-blind, randomized, placebo-controlled·n=2339High quality

TRIUMPH-1: Pivotal obesity trial without diabetes (Phase 3)

Obesity or overweight with a weight-related condition, without diabetes

Largest retatrutide trial to date. Weight loss of 28.3% (70.3 lb) at 12 mg, 25.9% (64.4 lb) at 9 mg, 19.0% (47.2 lb) at 4 mg vs. 2.2% (5.5 lb) placebo at 80 weeks. At 12 mg, 62.5% lost ≥25%, 45.3% lost ≥30% (bariatric-level), and 65.3% reached BMI <30. A 104-week extension (baseline BMI ≥35) reached up to 30.3% (85.0 lb). Dysesthesia 12.5% at 12 mg; AE discontinuations 11.3% vs. 4.9% placebo.

Nested basket sub-studies within TRIUMPH-1 (ADA 2026)

Beyond the main obesity cohort, TRIUMPH-1 embedded two "basket" sub-studies that produced the first reported retatrutide efficacy data for sleep apnea and the largest knee-OA dataset to date.[10]

  • Obstructive sleep apnea (n=243, moderate-to-severe): Retatrutide reduced the apnea-hypopnea index (AHI) by up to 36.1 events/hour (60.6%) from a baseline of 58.6 events/hour. This is brand-new efficacy evidence for retatrutide in OSA; the dedicated TRIUMPH-3 OSA trial has not yet reported.
  • Knee osteoarthritis (n=574): Retatrutide reduced WOMAC pain subscale scores by up to 4.3 points (a 73.1% placebo-adjusted reduction) from a baseline of 6.0 — consistent with the separate, dedicated TRIUMPH-4 knee-OA trial (n=445, reported December 2025). These are distinct studies and should not be conflated.

Where the evidence stands: The Phase 2 data is strong and well-published. Three Phase 3 topline readouts are now available — the pivotal TRIUMPH-1 (general obesity), TRIUMPH-4 (obesity/knee OA), and TRANSCEND-T2D-1 (T2D monotherapy) — and TRANSCEND-T2D-1 is now peer-reviewed in The Lancet. TRIUMPH-1 and TRIUMPH-4 remain press-release/conference data pending full publication. We are still waiting for TRIUMPH-2 (T2D + obesity), the dedicated TRIUMPH-3 (OSA) trial, plus FDA regulatory review. The evidence is maturing quickly, but retatrutide remains investigational.

What the evidence shows

Retatrutide has generated enormous interest as a potential "next generation" weight loss drug. Here's what the published research tells us about the most common claims:

Does retatrutide produce significant weight loss?

Yes. The pivotal Phase 3 TRIUMPH-1 trial (n=2,339, obesity without diabetes) showed 28.3% (70.3 lb) at 12 mg over 80 weeks vs. 2.2% placebo, with 45.3% of the 12 mg group losing ≥30% — comparable to bariatric surgery — and a 104-week extension reaching up to 30.3% (85.0 lb). Phase 2 data (n=338) showed up to 24.2% over 48 weeks; TRIUMPH-4 (n=445) showed 28.7% over 68 weeks; TRANSCEND-T2D-1 (n=537, T2D) showed 15.3% over 40 weeks. This exceeds semaglutide (~15%) and tirzepatide (~20-22%) in cross-trial comparisons.

Well-supported

Does retatrutide improve blood sugar in type 2 diabetes?

Yes. The peer-reviewed Phase 3 TRANSCEND-T2D-1 trial (n=537, published in The Lancet) showed A1C reductions of 1.69-1.94% vs. 0.81% placebo as monotherapy at 40 weeks (baseline A1C 7.9%), with 82-89% of treated participants reaching A1C below 7.0%. Weight loss reached 15.3% at 12 mg. Builds on Phase 2 data (n=281) showing HbA1c <6.5% in up to 82%. Additional Phase 3 data (TRIUMPH-2) still pending.

Well-supported

Does retatrutide reduce liver fat?

Yes. In a Phase 2a sub-study (n=98) of participants with MASLD, retatrutide reduced liver fat by up to 82.4% at 12 mg over 24 weeks. Normal liver fat levels (<5%) were achieved by 86% of the 12 mg group vs. 0% of placebo. The glucagon receptor agonism is thought to drive these hepatic effects beyond what GLP-1 agonists alone achieve.

Well-supported

Is retatrutide more effective than semaglutide or tirzepatide?

Cross-trial comparisons suggest potentially greater weight loss: retatrutide 28-30% (TRIUMPH-1) vs. tirzepatide 20-22% vs. semaglutide 13-17%. TRANSCEND-T2D-1 data was described by BMO Capital Markets as 'meaningfully better than previous tirzepatide data,' though RBC noted A1C reductions were somewhat worse vs. Mounjaro while weight loss and discontinuation rates favored retatrutide. No head-to-head trials exist. Cross-trial comparisons remain inherently unreliable.

Some supporting evidence

Does retatrutide help with knee osteoarthritis pain?

Yes. The dedicated TRIUMPH-4 trial (n=445) reduced WOMAC knee pain scores by up to 75.8% at 68 weeks, with over 1 in 8 patients becoming completely pain-free; both 9 mg and 12 mg doses met all primary and key secondary endpoints. A separate nested knee-OA cohort within TRIUMPH-1 (n=574) reduced WOMAC pain by up to 4.3 points (73.1%) from a baseline of 6.0. This is likely driven by the substantial weight loss reducing mechanical load on joints.

Well-supported

Does retatrutide improve obstructive sleep apnea?

Promising early evidence. A nested OSA cohort within TRIUMPH-1 (n=243, moderate-to-severe OSA) reduced the apnea-hypopnea index by up to 36.1 events/hour (60.6%) from a baseline of 58.6. These are the first reported retatrutide OSA efficacy data — from a topline ADA 2026 presentation, not a peer-reviewed publication — and the dedicated TRIUMPH-3 OSA trial has not yet reported.

Some supporting evidence

Does retatrutide protect against cardiovascular events?

Unknown. No cardiovascular outcomes data exists for retatrutide. The TRIUMPH-Outcomes trial is evaluating CV and kidney outcomes but has not reported results. Metabolic improvements from weight loss, glycemic control, and lipid changes are promising indirect evidence, but no dedicated CV outcomes dataset exists.

More research needed

Can you buy retatrutide now?

No. Retatrutide is not FDA-approved and is not available at pharmacies, through prescriptions, or from compounding facilities. It is only accessible through clinical trial enrollment. Any commercial sale is unauthorized. FDA approval is estimated no earlier than 2027-2028.

Not yet demonstrated

Safety & side effects

What clinical trials show

Retatrutide's safety profile is based on approximately 4,100 participants across Phase 2 and Phase 3 trials — including the pivotal TRIUMPH-1 obesity trial (n=2,339). The overall profile is consistent with the GLP-1 receptor agonist class, with some notable additions.[7]

Gastrointestinal events (the most common side effects): These are dose-dependent and typically most pronounced during dose escalation:

  • Nausea: 38-43% at therapeutic doses (vs. ~10% placebo)
  • Diarrhea: 33-35% (vs. ~13% placebo)
  • Vomiting: 20-21% (vs. ~0% placebo)
  • Constipation: 22-25% (vs. ~9% placebo)
  • Decreased appetite: 18-19% (vs. ~9% placebo)

GI side effects were mostly mild-to-moderate, transient, and occurred primarily during dose escalation. The Phase 2 trial demonstrated that slower dose escalation (starting at 2 mg rather than 4 mg) partially mitigated GI events.[1] TRANSCEND-T2D-1 showed lower GI rates at the highest dose (nausea 26.5%, diarrhea 22.8%, vomiting 17.6%), potentially reflecting optimized dose escalation in Phase 3.[9]

Dysesthesia: dose-dependent but variable across trials

Dysesthesia update — dose-dependent but variable across trials: In TRIUMPH-4, dysesthesia — an abnormal sense of touch — was reported in 8.8% (9 mg) and 20.9% (12 mg) vs. 0.7% placebo. The larger pivotal TRIUMPH-1 trial reported a clearer dose-response: 5.1% (4 mg), 12.3% (9 mg), and 12.5% (12 mg) vs. 0.9% placebo, while TRANSCEND-T2D-1 reported much lower rates: 4.5% (4 mg), 2.3% (9 mg), and 4.4% (12 mg). The spread may reflect differences in dose-escalation schedules, treatment duration (40 vs. 68 vs. 80 weeks), or patient population. The signal warrants monitoring but appears less alarming than TRIUMPH-4 alone suggested.[4][10][9][12]

Urinary tract infections: a new signal in TRIUMPH-1

TRIUMPH-1 surfaced a urinary tract infection (UTI) signal that had not appeared in the earlier retatrutide trials. UTIs were reported in 7.5% (4 mg), 8.8% (9 mg), and 8.4% (12 mg) of treated participants vs. 5.3% on placebo, and occurred predominantly in women. The infections were generally mild-to-moderate, mostly resolved during treatment, and rarely led to stopping the drug. A smaller, dose-dependent signal also appeared in TRANSCEND-T2D-1 (0.7%, 1.5%, and 2.9% across the 4/9/12 mg doses vs. 0% placebo). Investigators noted a possible link to hydration and said they will continue to monitor it as the program matures.[12]

Other safety concerns

  • Heart rate increase: Resting heart rate increases of 5-10 beats per minute have been observed, peaking around week 24. This is a class effect shared with GLP-1 receptor agonists.
  • Hypersensitivity reactions: Increased incidence reported in the meta-analysis. Serious hypersensitivity events were rare.
  • Acute pancreatitis: Reported in trials, though no causal link confirmed. Consistent with GLP-1 class warnings.
  • Lean mass loss: Expected with weight loss of this magnitude. Body composition data from Phase 2 sub-studies are being analyzed.
  • Unknown long-term safety: The longest reported data is TRIUMPH-1's 104-week extension. There is no post-marketing surveillance data. Long-term risks, including thyroid C-cell tumor risk (a concern for the GLP-1 class), are not yet characterized.

Treatment discontinuation

In the Phase 2 obesity trial, treatment discontinuation due to adverse events was relatively low across all dose groups. In the pivotal TRIUMPH-1 trial, AE-related discontinuations rose with dose: 11.3% at 12 mg vs. 4.9% on placebo (4.1% at 4 mg, 6.9% at 9 mg). In TRIUMPH-4, the discontinuation rate was described as manageable despite the 20.9% dysesthesia rate at 12 mg. TRANSCEND-T2D-1 discontinuation rates were described as favorable compared to the tirzepatide Phase 3 program.[10]

What we don't know about safety

There are important gaps in the retatrutide safety data:

  • No thyroid C-cell data in humans: GLP-1 receptor agonists carry a black box warning for thyroid C-cell tumors based on rodent studies. Retatrutide's risk has not been characterized.
  • No long-term (>104 week) data: The longest reported trial data is TRIUMPH-1's 104-week extension. Chronic, multi-year use safety is unknown.
  • No post-marketing surveillance: All data comes from controlled clinical trials. Real-world safety patterns may differ.
  • Glucagon receptor concerns: The added glucagon receptor agonism is novel. Long-term effects of chronic glucagon stimulation on hepatic glucose production, bone health, and other systems are poorly understood.
  • Dysesthesia mechanism unknown: Whether this is related to the glucagon receptor component, a dose-dependent drug effect, or an interaction remains unclear. The wide spread across trials at the same 12 mg dose — TRIUMPH-4 (20.9%), TRIUMPH-1 (12.5%), and TRANSCEND-T2D-1 (4.4%) — deepens this uncertainty.
  • No pregnancy data: Animal reproductive toxicity is expected but not fully characterized.
  • No drug interaction data: Formal drug interaction studies have not been published.

As of June 2026:

FDA status

Retatrutide is not FDA-approved for any indication. It is classified as an investigational drug undergoing Phase 3 clinical trials.

  • No approved retatrutide product: FDA states retatrutide is not a component of any FDA-approved drug and has not been found safe and effective for any condition.[11]
  • No Fast Track or Breakthrough Therapy designation has been publicly announced, though the strength of Phase 2 data makes one or both designations plausible.
  • Estimated timeline: As of June 2026, Eli Lilly has not publicly confirmed that an NDA has been filed. With the pivotal TRIUMPH-1 obesity trial now reported and TRANSCEND-T2D-1 published, an NDA submission could plausibly follow in 2026 or 2027, but no firm filing date has been announced. Standard FDA review takes 10-12 months; priority review could shorten this to 6 months. Earliest possible approval is estimated around 2027-2028 — and that timeline is not guaranteed.

How to access retatrutide today

The only legal way to access retatrutide is through enrollment in a clinical trial. The TRIUMPH and TRANSCEND programs have sites across multiple countries. Trial listings can be found at ClinicalTrials.gov by searching "retatrutide" or "LY3437943."[6]

For the focused legal-status breakdown, see Retatrutide Is Not Compoundable.

Warning: Any website, pharmacy, or supplier offering retatrutide for sale is operating outside regulatory boundaries. The drug has not been approved, cannot be legally prescribed, and cannot be legally compounded. Research-grade peptides sold online are unregulated and may not contain what they claim.

WADA / USADA status

Retatrutide is not prohibited under the 2026 WADA Prohibited List. GLP-1 receptor agonists sit on WADA's Monitoring Program rather than the Prohibited List — semaglutide since 2024, with markers of semaglutide and tirzepatide monitored both in- and out-of-competition from 2026 — meaning their use by athletes is tracked but does not constitute an anti-doping violation. As a GLP-1-containing triple agonist, retatrutide is not currently prohibited, though WADA could move the class to the Prohibited List in a future update if evidence of performance-enhancing misuse emerges.[8]

How retatrutide compares

Retatrutide's natural comparators are tirzepatide (dual agonist, same developer) and semaglutide (GLP-1 agonist, market leader). No head-to-head trials exist, so these comparisons rely on cross-trial data, which has important limitations:

Retatrutide

Not approved · Triple GIP/GLP-1/glucagon agonist

Weight loss (max dose)28-30%
HbA1c reductionUp to 82% <6.5%
CV outcomes dataNone
Liver fat reductionUp to 82%

Mechanism

GIP+GLP-1+GCG

Dosing

Weekly SC

Approved for

None (Phase 3)

Compounding

Not available

Tirzepatide

FDA-approved · Dual GIP/GLP-1 agonist

Weight loss (max dose)20-22%
HbA1c reduction2.0-2.6%
CV outcomes dataPending
Liver fat reductionModerate

Mechanism

GIP + GLP-1

Dosing

Weekly SC

Approved for

3 indications

Compounding

Not permitted

Semaglutide

FDA-approved · GLP-1 agonist

Weight loss (max dose)13-17%
HbA1c reduction1.5-1.9%
CV outcomes dataSELECT (proven)
Liver fat reductionModerate

Mechanism

GLP-1 only

Dosing

Weekly SC / oral

Approved for

3+ indications

Compounding

Limited access

The key tradeoffs:

  • Weight loss: Retatrutide leads in cross-trial comparisons (28-30% in TRIUMPH-1 vs. tirzepatide 20-22% vs. semaglutide 13-17%). The pivotal TRIUMPH-1 trial showed 28.3% at 80 weeks, with 45.3% of the 12 mg group losing ≥30%; TRANSCEND-T2D-1 showed 15.3% at 40 weeks in T2D. But no head-to-head trials exist.[10][4][9]
  • Liver fat reduction: Retatrutide leads decisively. The glucagon receptor component drives hepatic effects (82% reduction) not seen with GLP-1 or GIP/GLP-1 agonists.[3]
  • Cardiovascular protection: Semaglutide wins clearly. The SELECT trial (n=17,604) demonstrated a 20% reduction in MACE events. Neither tirzepatide nor retatrutide has CV outcomes data yet.
  • Safety track record: Semaglutide and tirzepatide have years of post-marketing data from millions of patients. Retatrutide has data from approximately 4,100 trial participants. The dysesthesia signal varies by trial — TRIUMPH-4 (20.9%), TRIUMPH-1 (12.5%), TRANSCEND-T2D-1 (4.4%) at 12 mg — and remains a concern to monitor.
  • Availability: Semaglutide and tirzepatide are FDA-approved and available by prescription. Retatrutide is not available outside clinical trials.
  • Oral option: Semaglutide has an oral formulation. Tirzepatide and retatrutide are injection-only.

The bottom line: retatrutide may eventually offer the strongest weight loss and metabolic benefits of the three, but it is years away from availability and has significantly less safety data. Semaglutide and tirzepatide are available now with robust evidence bases.

Related content

Guide

Retatrutide Is Not Compoundable

Focused legal-status guide explaining why retatrutide is trial-only and why research-use vendors are not equivalent to pharmacy access.

Peptide

Tirzepatide Profile

The dual GIP/GLP-1 agonist from Eli Lilly. FDA-approved for three indications. Retatrutide adds a third receptor (glucagon) to tirzepatide's dual mechanism.

Peptide

Semaglutide Profile

The GLP-1 agonist that pioneered the weight-loss peptide category. Retatrutide's cross-trial weight loss data substantially exceeds semaglutide.

Guide

What Are Peptides?

A foundational primer — helpful context for understanding retatrutide's triple-agonist mechanism.

News

TRANSCEND-T2D-1 Phase 3 Results

Breaking Phase 3 diabetes trial results — A1C reductions, weight loss data, and significantly lower dysesthesia rates than TRIUMPH-4.

News

Semaglutide Compounding Under Scrutiny

The regulatory landscape for GLP-1 agonists that shapes retatrutide's path to market.

Tool

Half-Life and Accumulation Plotter

Visualize how retatrutide's weekly dosing accumulates over time.

References

  1. [1]
    Jastreboff AM, Kaplan LM, Frias JP, et al.. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023. 389(6):514-526 DOI PubMedRCT

    Landmark Phase 2 RCT. n=338. Up to 24.2% weight loss at 12 mg dose over 48 weeks. Weight loss curves not yet plateaued.

  2. [2]
    Rosenstock J, Frias JP, Rodbard HW, et al.. “Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.” Lancet. 2023. 402(10401):529-544 DOI PubMedRCT

    Phase 2 RCT in T2D. n=281. HbA1c <6.5% in up to 82%. Active comparator (dulaglutide 1.5 mg).

  3. [3]
    Sanyal AJ, Kaplan LM, Frias JP, et al.. “Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.” Nat Med. 2024. 30(7):2037-2048 DOI PubMedRCT

    Phase 2a MASLD sub-study. n=98. Up to 82% liver fat reduction. 86% achieved normal liver fat at 12 mg. Glucagon receptor component may drive hepatic effects.

  4. [4]
    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.” 2025. LinkRCT

    Topline press release for TRIUMPH-4. n=445. 28.7% weight loss at 12 mg (68 weeks). Peer-reviewed publication pending. Dysesthesia signal at 20.9% (12 mg).

  5. [5]
    Coskun T, Urva S, Roell WC, et al.. “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Cell Metab. 2022. 34(9):1234-1247.e9 DOI PubMedAnimal study

    Key preclinical and Phase 1 paper from Eli Lilly discovery team. Establishes triple agonist receptor binding, preclinical pharmacology, and first-in-human PK/PD.

  6. [6]
    Giblin MJ, Kaplan LM, Somers VK, et al.. “Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials.” Diabetes Obes Metab. 2026. DOI PubMedReview

    Design rationale paper for TRIUMPH Phase 3 program. Describes novel basket trial design across obesity, OSA, and knee OA.

  7. [7]
    Wang Y, Liu J, Zhang X, et al.. “Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.” Front Endocrinol. 2025.Systematic review

    Meta-analysis of 3 Phase 2 RCTs (n=878). Confirms dose-dependent weight loss and GI-dominant safety profile. Pre-dates Phase 3 data.

  8. [8]
    World Anti-Doping Agency. “The 2026 Prohibited List — International Standard.” 2026. Link
  9. [9]
    Bajaj HS, Frias JP, Rosenstock J, et al.. “Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.” Lancet. 2026. LinkRCT

    First peer-reviewed Phase 3 RCT for retatrutide (online June 6, 2026). n=537. Monotherapy vs. placebo. A1C reductions of 1.69%/1.86%/1.94% at 4/9/12 mg vs. 0.81% placebo (baseline 7.9%); 82-89% reached A1C <7.0%. Weight loss 15.3% at 12 mg in the Lancet analysis (the March 2026 topline press release reported 16.8% / 36.6 lb). Dysesthesia 2.3-4.5%.

  10. [10]
    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.” 2026. LinkRCT

    Topline press release (May 21, 2026) and ADA 2026 presentation for the pivotal TRIUMPH-1 obesity trial (NCT05929066). n=2,339, 80 weeks. Weight loss 28.3% (70.3 lb) at 12 mg, 25.9% (9 mg), 19.0% (4 mg) vs. 2.2% placebo; 45.3% lost ≥30% at 12 mg; 65.3% reached BMI <30; 104-week extension up to 30.3% (85.0 lb). Dysesthesia 12.5% at 12 mg; AE discontinuations 11.3% vs. 4.9% placebo. Nested baskets: OSA (n=243) AHI −36.1 events/hr (60.6%); knee OA (n=574) WOMAC pain −4.3 points (73.1%). Peer-reviewed publication pending.

  11. [11]
    U.S. Food and Drug Administration. “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” 2026. LinkSafety study

    FDA safety communication stating retatrutide cannot be used in compounding under federal law and warning about GLP-1 products falsely labeled for research purposes or not for human consumption.

  12. [12]
    Eli Lilly and Company. “Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications.” 2026. LinkConference abstract

    Eli Lilly ADA 2026 topline release (June 6, 2026) for TRIUMPH-1; source for the new UTI safety signal and per-dose dysesthesia rates.

Medical disclaimer

Peptide Garden is an educational resource, not a medical provider. The information on this page is compiled from published research, clinical trial data, and peer-reviewed journals. It is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Retatrutide is an investigational drug that is not FDA-approved and is not available by prescription. It is only accessible through clinical trial enrollment. Always consult a qualified healthcare provider before making decisions about any medication or clinical trial participation.